31 October 2023
Scancell Holdings plc
("Scancell" or the "Company")
Annual Report and Notice of Annual General Meeting
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that the Company's Annual Report and Accounts for the year ended 30 April 2023 and Notice of Annual General Meeting ("AGM") will be sent to shareholders shortly.
The Annual Report and Accounts for the year ended 30 April 2023 is available on the Company's website at: https://www.scancell.co.uk/investors/financial-info.
The AGM will be held at 2:00 p.m. GMT at the offices of Cooley (UK) LLP at 22 Bishopsgate, London EC2N 4BQ on Wednesday 29 November 2023.
After the AGM, Scancell's senior management team will be presenting the final results for the year ended 30 April 2023 followed by a Q&A session, and all shareholders are invited to attend in person. A copy of the presentation will also be made available on the Company's Documents & Presentations section following the presentation.
- ENDS-
| For further information, please contact: | |
| | |
| Scancell Holdings plc | +44 (0) 20 3709 5700 |
| Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
| |
| Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7710 7600 |
| Nicholas Moore/Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking) |
|
| Nick Adams/Nick Harland (Corporate Broking)
|
|
| Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
| Freddy Crossley/Emma Earl (Corporate Finance) |
|
| Rupert Dearden (Corporate Broking) |
|
| ICR Consilium | +44 (0) 20 3709 5700 |
| Mary-Jane Elliott/Matthew Neal/Chris Welsh |
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
